New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.

MLA

Tazarki, Helmi, et al. “New Pyrido[3,4-g]Quinazoline Derivatives as CLK1 and DYRK1A Inhibitors: Synthesis, Biological Evaluation and Binding Mode Analysis.” European Journal of Medicinal Chemistry, vol. 166, Mar. 2019, pp. 304–17. EBSCOhost, https://doi.org/10.1016/j.ejmech.2019.01.052.

APA

Tazarki, H., Zeinyeh, W., Esvan, Y. J., Knapp, S., Chatterjee, D., Schröder, M., Joerger, A. C., Khiari, J., Josselin, B., Baratte, B., Bach, S., Ruchaud, S., Anizon, F., Giraud, F., & Moreau, P. (2019). New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis. European Journal of Medicinal Chemistry, 166, 304–317. https://doi.org/10.1016/j.ejmech.2019.01.052

Chicago

Tazarki, Helmi, Wael Zeinyeh, Yannick J Esvan, Stefan Knapp, Deep Chatterjee, Martin Schröder, Andreas C Joerger, et al. 2019. “New Pyrido[3,4-g]Quinazoline Derivatives as CLK1 and DYRK1A Inhibitors: Synthesis, Biological Evaluation and Binding Mode Analysis.” European Journal of Medicinal Chemistry 166 (March): 304–17. doi:10.1016/j.ejmech.2019.01.052.